SHANGHAI, China, Jan. 20 China-Biotics, Inc.(Nasdaq: CHBT) ("China-Biotics," "the Company"), a leading Chinese firmspecializing in the manufacture, research, development, marketing anddistribution of probiotics products, today announced the State Food and DrugAdministration has approved manufacturing certificates for the production ofseveral new products, including Synbiotics Capsules, Probiotics Gegen Capsules,Probiotics Tremella Polysaccharide Capsules and Probiotics Chewable Tablets.
"These new certificates will enable us to successfully expand our productportfolio," said Mr. Jinan Song, China-Biotics' Chairman and Chief ExecutiveOfficer. "The launch of the new products will better serve our existingcustomers and support our continuing regional retail expansion."
The new probiotics-based products were developed during an eight-monthprocess and are currently in production at the Company's existingmanufacturing facility.
The products are intended to offer several different health solutions toconsumers. Synbiotics Capsules' primary active ingredients are lactobacillusthermophilus, infant bifidobacterium, bifidobacterium bifidum and oligo-fructose, which can enhance adolescents' immune systems and gastrointestinal("GI") health. Probiotics Gegen Capsules' primary active ingredients arelactobacillus acidophilus and bifidobacterium bifidum ("LA-BB") and gegenpowder, a traditional Chinese medicinal herb, which can enhance women's GIhealth and relieve menopausal symptoms. Probiotics Tremella PolysaccharideCapsules' primary active ingredients are LA-BB and tremella polysaccharide,which can enhance the GI health and immune systems of seniors. ProbioticsChewable Tablets' primary active ingredients are lactobacillus acidophilus,infant bifidobacterium and taurine, which can reduce the creation of entericpathogenic bacteria and increase consumers' energy levels.
"For the past few years, we have devoted significant resources in theresearch and development of different kinds of new products, as well aseducating the public about the benefits of probiotics," said Mr. Song. "Inaddition to an in-house R&D team of more than 30 researchers, we also haveextensive relationships with academic institutions, including a post-doctoralresearch center in partnership with the Northeast Agricultural University ofChina. Our success has attracted and will continue to attract more talentedpeople to health-related careers with China-Biotics. This success will enableus to further promote probiotics-based products through our R&D capabilitiesand our in-depth knowledge of the nutritional supplement market in China."
About China-Biotics, Inc.
China-Biotics, Inc. ("China-Biotics," "the Company"), a leadingmanufacturer of biotechnology products and supplements, engages in theresearch, development, marketing and distribution of probiotics dietarysupplements. Through its wholly owned subsidiary, Shanghai ShiningBiotechnology Co., Ltd., the Company has operations in Shanghai. Itsproprietary product portfolio contains live microbial nutritional supplementsunder the "Shining" brand. Currently, the products are sold OTC through largedistributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang.China-Biotics plans to launch 300 Shining brand retail outlets in major citiesin China. Currently, China-Biotics is strategically expanding its productioncapacity of probiotics to meet growing demand in the bulk additive market.For more information, please visit http://www.chn-biotics.com .
Safe Harbor Statement Under the Private Securities Litigation Reform Actof 1995: Any statements set forth above that are not historical facts areforward-looking statements that involve risks and uncertainties that couldcause actual results to differ materially from those in the forward-lookingstatements. Such factors include, but are not limited to, the Company'sability to market existing and new products, ability to access to capital forexpansion, and changes from anticipated levels of sales, future national orregional economic and competitive conditions, market acceptance of its retailstore concept, changes in relationships with customers, dependence on itsflagship product profits and other factors detailed from time to time in theCompany's filings with the United States Securities and Exchange Commissionand other regulatory authorities. The Company undertakes no obligation topublicly update or revise any forward-looking statements, whether as a resultof new information, future events or otherwise.For more information, please contact: CCG Investor Relations Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: firstname.lastname@example.org Web: http://www.ccgirasia.com
SOURCE China-Biotics, Inc.